Leerink Partnrs Forecasts Stronger Earnings for Equillium

Equillium, Inc. (NASDAQ:EQ) – Equities researchers at Leerink Partnrs upped their FY2025 earnings estimates for Equillium in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.83) for the year, up from their prior estimate of ($1.50). The consensus estimate for Equillium’s current full-year earnings is ($0.02) per share.

Equillium Stock Down 10.1 %

Shares of EQ opened at $0.77 on Monday. The business’s 50 day moving average price is $0.70 and its 200-day moving average price is $0.81. Equillium has a 52 week low of $0.49 and a 52 week high of $3.25. The stock has a market cap of $27.28 million, a P/E ratio of -5.50 and a beta of 1.79.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC raised its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 300,400 shares of the company’s stock after acquiring an additional 91,200 shares during the period. Renaissance Technologies LLC owned approximately 0.85% of Equillium worth $208,000 as of its most recent SEC filing. 27.05% of the stock is owned by institutional investors.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.